Replies to post #204551 on Biotech Values

[DewDiligence]

There was no need for ACHN trading to be halted, IMO. The data reported today are not much different from those reported two weeks ago (#msg-125053249).

[DewDiligence]

JNJ/ACHN—3-DAA* HCV regimen has good-news/bad-news—mostly bad:

http://finance.yahoo.com/news/achillion-announces-additional-phase-2-070000940.html

The good news is for non-cirrhotic GT1 patients, where 6- and 8-week durations produced 100% (20/20) SVR.

The bad news is that this regimen is being discontinued as a treatment for GT3 patients, and hence it’s not in the running for a universal pan-genotypic treatment.

The SVR data for (non-cirrhotic) GT3 patients were awful: 77% (10/13) for the 12-week duration, and 0% (0/5) for the 8-week duration.

Nice call by ‘willy’ in #msg-125355802.

*Simeprevir (PI), Odalasvir (NS5A), and AL-335 (nuke).